Alzamend Neuro, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2023 Annual Meeting of Stockholders held on April 26, 2023. As of the record date of March 31, 2023, there were 96,940,124 shares of common stock issued and outstanding entitled to vote.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
Stockholders voted on four proposals, all of which were approved or ratified:
- Proposal 1 (Election of Directors): Seven directors were elected to serve until the 2024 Annual Meeting. All nominees received majority support, with "For" votes ranging from approximately 46.7 million to 49.2 million.
- Proposal 2 (Say-on-Pay): Stockholders approved the advisory vote on executive compensation with 48,354,282 votes "For" and 1,332,190 "Against."
- Proposal 3 (Say-on-Frequency): Stockholders approved holding future advisory votes on executive compensation every three years. The "3 Years" option received 39,734,366 votes, compared to 9,530,011 for "1 Year" and 712,873 for "2 Years."
- Proposal 4 (Auditor Ratification): Stockholders ratified the selection of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending April 30, 2023, with 49,628,290 votes "For."
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It strictly reports the outcomes of the shareholder vote.
Investor Verification Checklist
- Verify the definitive proxy statement (Schedule 14A) filed on March 31, 2023, for detailed biographies of the elected directors and executive compensation tables.
- Confirm the fiscal year-end date of April 30, 2023, when reviewing upcoming financial reports.
- Note that the company has elected to hold future say-on-pay votes every three years.
- Review the company's latest 10-K or 10-Q filings for actual financial performance metrics, as this 8-K contains none.